PURLs

Can vitamin D prevent acute respiratory infections?

Author and Disclosure Information

 

References

This study found that low-dose daily or weekly vitamin D supplementation was protective against acute respiratory tract infections, but bolus dosing was not.

In 2-step analysis, patients benefited who: had baseline circulating 25-hydroxyvitamin D concentrations < 10 ng/mL (AOR = 0.30; 95% CI, 0.17-0.53; NNT = 4); had baseline circulating 25-hydroxyvitamin D levels of 10 to 28 ng/mL (AOR = 0.75; 95% CI, 0.60-0.95; NNT = 15); were ages 1.1 to 15.9 years (AOR = 0.59; 95% CI, 0.45-0.79); were ages 16 to 65 years (AOR = 0.79; 95% CI, 0.63-0.99); or had a body mass index < 25 (AOR = 0.82; 95% CI, 0.71-0.95).

Higher D levels are a different story. Vitamin D supplementation in people with circulating levels of 25-hydroxyvitamin D ≥ 30 ng/mL did not appear to provide benefit (AOR = 0.96; 95% CI, 0.78-1.18). Supplementation in this population did not influence any of the secondary outcomes, including risk for all-cause serious adverse events (AOR = 0.98; 95% CI, 0.80-1.20).

WHAT’S NEW

A more accurate snapshot

Previous studies of vitamin D and respiratory tract infections were mostly observational in nature. Those that were RCTs used variable doses of vitamin D, had variable baseline 25-hydroxyvitamin D levels, and employed various methods to monitor ARTI symptoms/incidence.5-8 This is the first systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials with supplementation using vitamin D3 or vitamin D2 that used individual participant-level data, which gives a more accurate estimate of outcomes when compared with traditional meta-analyses.

CAVEATS

Only the most deficient benefit?

Vitamin D supplementation was safe and protected against ARTIs overall, but the greatest effect of vitamin D supplementation on the prevention of ARTIs was noted in those who were most severely vitamin D deficient (those with circulating 25-hydroxyvitamin levels < 10 ng/mL, NNT = 4; 10-28 ng/mL, NNT = 15). There was no demonstrable effect once circulating 25-hydroxyvitamin D levels reached 30 ng/mL.

CHALLENGES TO IMPLEMENTATION

Breaking tradition

The study found that both daily and weekly doses of vitamin D were effective in reducing the incidence of ARTIs, but the doses used were much lower than the commonly used 10,000 to 50,000 IU bolus doses, which were ineffective in reducing ARTIs in the current meta-analysis. Since bolus dosing is an ingrained practice for many providers, changing this may prove challenging.

Continue to: In addition...

Copyright © 2019. The Family Physicians Inquiries Network. All rights reserved.

Online-Only Materials

AttachmentSize
PDF icon jfp06805230_methodology.pdf435.44 KB

Recommended Reading

No clear benefit seen for postdischarge oxygen in preemies with BPD
MDedge Family Medicine
Busiest week yet brings 2019 measles total to 555 cases
MDedge Family Medicine
New sleep apnea guidelines offer evidence-based recommendations
MDedge Family Medicine
Pulmonologist: In COPD, try dual therapy before adding corticosteroid
MDedge Family Medicine
Teen e-cigarette use: A public health crisis
MDedge Family Medicine
Measles cases for 2019 now at postelimination high
MDedge Family Medicine
Long-term antibiotic use may heighten stroke, CHD risk
MDedge Family Medicine
Combo respiratory pathogen tests miss pertussis
MDedge Family Medicine
Most measles cases in 25 years prompts government pleas to vaccinate
MDedge Family Medicine
PCV13 vaccine reduces frequency of otitis media visits
MDedge Family Medicine